Effects of Tacrolimus on the Expression of MDR1 in Adriamycin Induced Nephropathy Rats

Yan-min ZHANG,Li-hua NIE,Jie GUO,Qi-hua FENG

DOI: https://doi.org/10.3969/j.issn.1009-881X.2017.01.006

2017-01-01

Abstract:Objective To investigate the effect of tacrolimus on the expression of MDR1 in renal tissue of rats with adriamycin nephropathy. Methods The rat model of nephropathy was established by unilateral nephrectomy combined with adriamycin injection via tail vein. After successful model, the rats were divided into five groups: group A (control group), group B (model group), group C (hormone sensitive group), group D (tacrolimus treatment group), and group E (steroid resistant group). Blood samples were collected at 0, 4, 6, 12 weeks of the experiment. The urine of rats was collected from the metabolic cage for 24 h, to detect 24 h urinary protein in rats. The MDR1 expression in renal tissue was detected by real time PCR (RT-PCR). Results (1)24 h urinary protein and total cholesterol of rats in group B for 4, 6 and 8 weeks were higher than those of group A (P<0.01), serum albumin was lower than that of group A (P<0.01); 24 h urine protein and total cholesterol of rats in group C for 6 weeks and 8 weeks were lower than those of group B (P<0.01), serum albumin was higher than that of group B (P<0.01); 24 h urinary protein and total cholesterol of rats in group D for 12 weeks and 8 weeks decreased (P<0.01), the serum albumin elevated (P<0.01). (2)MDR1 was expressed in renal tissue of rats in each group, MDR1 of renal tissue at the end of the 8 weeks of rats in group B, group C, group D and group E were significantly higher than that in group A (P<0.05), the MDR1 expression of renal tissue in rats of 12 weeks in group D was lower than that of 8 weeks (P<0.05), and was lower than that in group C (P<0.01). Conclusion The reversal of high expression of MDR1 in renal tissue of rats with adriamycin nephropathy may be one of the comprehensive mechanism of tacrolimus in the treatment of steroid resistant nephrotic syndrome, which provides theoretical basis for clinical use of tacrolimus in the treatment of steroid resistant nephrotic syndrome.